ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,297.10
-0.21%
US Tech 100
18,079.20
-0.20%
다우존스 지수
39,869.38
-0.10%
Bitcoin
65,597.93
0.55%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Lumos Pharma Inc (LUMO)

  7. Lumos Pharma Inc (LUMO) 뉴스

LUMO Lumos Pharma Inc

2.60
0.36 (16.07%)
17 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Lumos Pharma Inc LUMO 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.36 16.07% 2.60 08:39:39
개장가 저가 고가 종가 전일 종가
2.22 2.22 2.67 2.63 2.24
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
15/05/202422:57EDGAR2Form 8-K - Current report
15/05/202405:15GLOBELumos Pharma Announces Positive End-of-Phase 2 Meeting with..
10/05/202403:51GLOBELumos Pharma to Report First Quarter 2024 Financial Results..
19/04/202405:05GLOBELumos Pharma Announces Abstracts Accepted for Presentation..
20/03/202421:00GLOBELumos Pharma Announces that the USPTO Has Granted Patent..
08/03/202406:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/03/202406:44EDGAR2Form 8-K - Current report
08/03/202406:01GLOBELumos Pharma Reports Full Year 2023 Financial Results and..
26/02/202423:00GLOBELumos Pharma to Report Full Year 2023 Financial Results and..
08/02/202407:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/02/202406:02EDGAR2Form 144 - Report of proposed sale of securities
06/02/202407:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202407:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202407:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202407:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202407:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202406:05GLOBELumos Pharma to Participate in Oppenheimer’s 34th Annual..
11/01/202409:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/01/202406:34EDGAR2Form 8-K - Current report
05/01/202406:05GLOBELumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to..
30/11/202306:30EDGAR2Form SC 13D/A - General statement of acquisition of..
22/11/202306:15GLOBELumos Pharma to Host Virtual Key Opinion Leader Webinar to..
21/11/202306:05GLOBELumos Pharma Announces Participation in the Piper Sandler..
16/11/202306:38EDGAR2Form 8-K - Current report
08/11/202308:24DJNLumos Pharma Shares Than Double After Hormone Deficiency..
08/11/202307:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202306:42EDGAR2Form 8-K - Current report
08/11/202306:35GLOBELumos Pharma Reports Third Quarter 2023 Financial Results..
08/11/202306:08EDGAR2Form 8-K - Current report
08/11/202306:01GLOBELumos Pharma Announces Topline Data from Phase 2..
27/09/202305:34EDGAR2Form 8-K - Current report
26/09/202322:00GLOBELumos Pharma Announces New Data and Analysis of 15 Subjects..
14/09/202321:00GLOBELumos Pharma Announced Abstract Accepted for Oral..
08/09/202305:34GLOBELumos Pharma Announces Participation in Investor Conferences..
22/08/202322:00GLOBEIndependent Panel of Renowned Pediatric Endocrinologists to..
10/08/202322:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/08/202305:36EDGAR2Form 8-K - Current report
10/08/202305:01GLOBELumos Pharma Reports Second Quarter 2023 Financial Results,..
04/08/202305:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/08/202305:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/08/202304:54EDGAR2Form 144 - Report of proposed sale of securities
26/07/202322:00GLOBELumos Pharma to Report Second Quarter 2023 Financial Results..
12/07/202321:00GLOBELumos Pharma to Participate in the Oppenheimer 2023 Montauk..
29/06/202305:26EDGAR2Form 8-K - Current report
29/06/202305:01GLOBELumos Pharma Announces Departure of Chief Medical Officer
21/06/202322:00GLOBELumos to Highlight New LUM-201 Data and Analysis Presented ..
31/05/202321:00GLOBELumos Pharma to Participate in the Upcoming 2023 BIO..
25/05/202321:00GLOBELumos Pharma Announces Abstracts Accepted for Oral..
22/05/202322:00GLOBELumos Pharma to Participate in World Orphan Drug Congress..

최근 히스토리

NASDAQ
LUMO
Lumos Pharma
NASDAQ
LMRKP
Landmark Infrastructure ...
LSE
SSWA
BIT
UB6SWK
Unicredit Bank
BIT
FRV5LL
Vontobel
BIT
SOLR
Invesco Solar Energy UCI...
ASX
NMGN
TG
GRB
SEB
AMEX
OCTT
Allianzim US Large Cap B...
LSE
0DNT
Aurskog Sparebank
BIT
UC5R4V
Unicredit Bank
BIT
S29237
Societe Generale Effekten
BIT
I08073
Intesa Sanpaolo
COIN
YFIDETH
YFIDapp
LSE
SE63
Bank Nova.25
FX
SLLEUR
SLL vs Euro
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유